CSF1R and tenosynovial giant cell tumor: Several clinically investigational CSF1R inhibitors (CSF1Ri), either TKIs or antibodies18–20, are being developed, but with limited success, except for tenosynovial giant cell tumors (TGCT), where CSF1R alteration is the sole driver of the disease21.